Circulating Levels of Human Salusin-β, a Potent Hemodynamic and Atherogenesis Regulator
Overview
Authors
Affiliations
Using bioinformatics analysis, we previously identified salusin-β, an endogenous bioactive peptide with diverse physiological activities. Salusin-β is abundantly expressed in the neuroendocrine system and in systemic endocrine cells/macrophages. Salusin-β acutely regulates hemodynamics and chronically induces atherosclerosis, but its unique physicochemical characteristics to tightly adhere to all types of plastic and glassware have prevented elucidation of its precise pathophysiological role. To quantitate plasma total salusin-β concentrations, we produced rabbit and chicken polyclonal antibodies against the C- and N-terminal end sequences, circumvented its sticky nature, and successfully established a sandwich enzyme-linked immunosorbent assay (ELISA). Salusin-β was abundantly present in the plasma of healthy volunteers, ranging from 1.9 to 6.6 nmol/L. Reverse phase-high performance liquid chromatography analysis showed that a single immunoreactive salusin-β peak coincided with synthetic authentic salusin-β. Plasma salusin-β concentrations were unaffected by postural changes and by potent vasopressin release stimuli, such as hypertonic saline infusion or smoking. However, salusin-β concentrations showed significant circadian variation; concentrations were high during the daytime and reached the lowest concentrations in the early morning. Plasma salusin-β levels in subjects with diabetes mellitus, coronary artery disease, and cerebrovascular disease showed distinctly higher levels than healthy controls. Patients with panhypopituitarism combined with complete central diabetes insipidus also showed significantly higher plasma salusin-β levels. Therefore, the ELISA system developed in this study will be useful for evaluating circulating total salusin-β levels and for confirming the presence of authentic salusin-β in human plasma. The obtained results suggest a limited contribution of the neuroendocrine system to peripheral total salusin-β concentrations and a role for plasma total salusin-β concentrations as an indicator of systemic vascular diseases.
Serum salusin-α and -β levels in patients with parkinson's disease.
Algul F, Koc E, Kaya H Neurol Sci. 2023; 45(2):585-590.
PMID: 37668828 DOI: 10.1007/s10072-023-07031-0.
Serum salusin-β levels in patients with systemic lupus erythematosus.
Hajialilo M, Jorjani R, Rahimi M, Ghorbanihaghjo A, Malek Mahdavi A, Ghojazadeh M Clin Rheumatol. 2023; 42(8):2097-2103.
PMID: 37120490 DOI: 10.1007/s10067-023-06610-y.
Xu Y, Pan Y, Wang X, Chen A, Tang X, Liu X Oxid Med Cell Longev. 2021; 2021:8896226.
PMID: 34422210 PMC: 8373485. DOI: 10.1155/2021/8896226.
Salusin‑β participates in high glucose‑induced HK‑2 cell ferroptosis in a ‑dependent manner.
Wang W, Jiang X, Gao C, Chen Z Mol Med Rep. 2021; 24(3).
PMID: 34296310 PMC: 8335735. DOI: 10.3892/mmr.2021.12313.
Argun D, Argun F, Uysal B Ir J Med Sci. 2021; 190(4):1403-1411.
PMID: 34109528 DOI: 10.1007/s11845-021-02674-4.